On June 6, 2018 Protagonist Therapeutics, Inc. (Nasdaq:PTGX) reported that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2018 JMP Securities Life Sciences Conference taking place June 20-21 at the St. Regis Hotel in New York, NY (Press release, Protagonist, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353461 [SID1234527210]). The Protagonist Therapeutics presentation is scheduled for Wednesday, June 20, at 2 p.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast of the presentation can be accessed by visiting the Investors page of the Protagonist Therapeutics corporate website at View Source

On June 6, 2018 Pieris Pharmaceuticals, Inc. presented the Jefferies Global Healthcare Conference presentation of Pieris Pharmaceuticals, Inc (Presentation, Pieris Pharmaceuticals, JUN 6, 2018, View Source [SID1234527206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 6, 2018 Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that has entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732 (Press release, Moleculin, JUN 6, 2018, View Source [SID1234527205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"WP1732, which we believe, based on preclinical testing, is a breakthrough discovery, is now advancing to the stage of formulation development," commented Walter Klemp, Moleculin’s Chairman and CEO. "With the demand for clinical testing of WP1066 continuing to grow, it is easy to forget that we believe WP1732 represents a major expansion of our STAT3 inhibition capability by providing a highly soluble alternative that is ideally suited for IV administration. This agreement marks the beginning of our creating a preclinical package to submit to the FDA in order to request Investigational New Drug status."

On June 6, 2018 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will be webcasting its corporate presentation at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA (Press release, Jazz Pharmaceuticals, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353592 [SID1234527204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update at the conference on Wednesday, June 13, 2018 at 9:20 a.m. PDT / 5:20 p.m. IST.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at View Source Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at View Source

On June 6, 2018 IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, reported that Yujiro S. Hata, chief executive officer of IDEAYA, will present at the Jefferies Global Healthcare Conference in New York City at 2:30 p.m. EDT on Thursday, June 7 (Press release, Ideaya Biosciences, JUN 6, 2018, View Source [SID1234527202]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details
Event: 2018 Jefferies Global Healthcare Conference
Date: Thursday, June 7, 2018
Time: 2:30 p.m. EDT
Location: New York, NY
Website: View Source